Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20089646 | 0.81 | VRK1 (0.32) | ALOX5APPDE2A | |
| SCHEMBL20095651 | 0.80 | PDE2A (0.33) | ALOX5APPDE2A | |
| SCHEMBL19505066 | 0.76 | ALOX5AP (0.36) | ALOX5AP | |
| SCHEMBL19833139 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL19069922 | 0.73 | GRIN2B (0.33) | — | |
| SCHEMBL19504326 | 0.72 | ALOX5AP (0.40) | ALOX5APPDE2A | |
| SCHEMBL19497736 | 0.71 | HDAC1 (0.33) | PDE2A | |
| SCHEMBL18649026 | 0.71 | RIPK1 (0.40) | PDE2A | |
| SCHEMBL20089643 | 0.71 | CYP2A6 (0.34) | — | |
| SCHEMBL19833099 | 0.70 | ESR1 (0.31) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3640251-B1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2021-12-08 | — | — | EP | disclosed |
| US-20210284636-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA PHARMACEUTICALS LP | 2021-09-16 | — | — | US | disclosed |
| EP-3640251-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2020-04-22 | — | — | EP | disclosed |
| WO-2018077630-A1 | 6,7,8,9-TETRAHYDRO-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284636-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | ALOX5AP 2336/4885PDE2A 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.